Percutaneous pulmonic valve implantation

Ziyad M. Hijazi, Arun Kumar, Clifford Kavinsky, Zahid Amin

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Opinion statement: Surgically placed valve conduits between the right ventricle and pulmonary artery often fail within 10 years. The failure may be the result of insufficiency, stenosis, or often a combination of the two. Pulmonic valve insufficiency may lead to right ventricular dilatation, heart failure, arrhythmias, and death. Reoperation requires cardiopulmonary bypass, which may aggravate an already failing right ventricle, and is associated with a higher risk of death and significant morbidity. Therefore, percutaneous implantation of a pulmonic valve is an attractive option to improve hemodynamic function and ameliorate symptoms. Initial experience with various types of percutaneous pulmonary valve systems demonstrates the procedure to be effective and safe. Improvements in technique and device modification are evolving rapidly. Studies and clinical follow-up are ongoing to further assess functional improvement, freedom from adverse cardiac events, and longevity of percutaneously implanted valves.

Original languageEnglish (US)
Pages (from-to)483-491
Number of pages9
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume11
Issue number6
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Heart Ventricles
Pulmonary Valve
Lung
Cardiopulmonary Bypass
Reoperation
Pulmonary Artery
Cardiac Arrhythmias
Dilatation
Pathologic Constriction
Heart Failure
Hemodynamics
Morbidity
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous pulmonic valve implantation. / Hijazi, Ziyad M.; Kumar, Arun; Kavinsky, Clifford; Amin, Zahid.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 11, No. 6, 01.01.2009, p. 483-491.

Research output: Contribution to journalReview article

Hijazi, Ziyad M. ; Kumar, Arun ; Kavinsky, Clifford ; Amin, Zahid. / Percutaneous pulmonic valve implantation. In: Current Treatment Options in Cardiovascular Medicine. 2009 ; Vol. 11, No. 6. pp. 483-491.
@article{461e173ba5b1450786098fce726e9139,
title = "Percutaneous pulmonic valve implantation",
abstract = "Opinion statement: Surgically placed valve conduits between the right ventricle and pulmonary artery often fail within 10 years. The failure may be the result of insufficiency, stenosis, or often a combination of the two. Pulmonic valve insufficiency may lead to right ventricular dilatation, heart failure, arrhythmias, and death. Reoperation requires cardiopulmonary bypass, which may aggravate an already failing right ventricle, and is associated with a higher risk of death and significant morbidity. Therefore, percutaneous implantation of a pulmonic valve is an attractive option to improve hemodynamic function and ameliorate symptoms. Initial experience with various types of percutaneous pulmonary valve systems demonstrates the procedure to be effective and safe. Improvements in technique and device modification are evolving rapidly. Studies and clinical follow-up are ongoing to further assess functional improvement, freedom from adverse cardiac events, and longevity of percutaneously implanted valves.",
author = "Hijazi, {Ziyad M.} and Arun Kumar and Clifford Kavinsky and Zahid Amin",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s11936-009-0051-3",
language = "English (US)",
volume = "11",
pages = "483--491",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Percutaneous pulmonic valve implantation

AU - Hijazi, Ziyad M.

AU - Kumar, Arun

AU - Kavinsky, Clifford

AU - Amin, Zahid

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Opinion statement: Surgically placed valve conduits between the right ventricle and pulmonary artery often fail within 10 years. The failure may be the result of insufficiency, stenosis, or often a combination of the two. Pulmonic valve insufficiency may lead to right ventricular dilatation, heart failure, arrhythmias, and death. Reoperation requires cardiopulmonary bypass, which may aggravate an already failing right ventricle, and is associated with a higher risk of death and significant morbidity. Therefore, percutaneous implantation of a pulmonic valve is an attractive option to improve hemodynamic function and ameliorate symptoms. Initial experience with various types of percutaneous pulmonary valve systems demonstrates the procedure to be effective and safe. Improvements in technique and device modification are evolving rapidly. Studies and clinical follow-up are ongoing to further assess functional improvement, freedom from adverse cardiac events, and longevity of percutaneously implanted valves.

AB - Opinion statement: Surgically placed valve conduits between the right ventricle and pulmonary artery often fail within 10 years. The failure may be the result of insufficiency, stenosis, or often a combination of the two. Pulmonic valve insufficiency may lead to right ventricular dilatation, heart failure, arrhythmias, and death. Reoperation requires cardiopulmonary bypass, which may aggravate an already failing right ventricle, and is associated with a higher risk of death and significant morbidity. Therefore, percutaneous implantation of a pulmonic valve is an attractive option to improve hemodynamic function and ameliorate symptoms. Initial experience with various types of percutaneous pulmonary valve systems demonstrates the procedure to be effective and safe. Improvements in technique and device modification are evolving rapidly. Studies and clinical follow-up are ongoing to further assess functional improvement, freedom from adverse cardiac events, and longevity of percutaneously implanted valves.

UR - http://www.scopus.com/inward/record.url?scp=70449484483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449484483&partnerID=8YFLogxK

U2 - 10.1007/s11936-009-0051-3

DO - 10.1007/s11936-009-0051-3

M3 - Review article

C2 - 19930986

AN - SCOPUS:70449484483

VL - 11

SP - 483

EP - 491

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 6

ER -